Navigation Links
Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification

SALT LAKE CITY, UT, June 11, 2007 (MARKET WIRE via COMTEX News Network) -- Myriad Genetics, Inc. (NASDAQ: MYGN) (www.myriad.com) announced today that it presented a mathematical comparison of a "Staggered Start" and a "Randomized Withdrawal" clinical trial design with a "Natural History Staggered Start" clinical trial design at the Alzheimer's Association Prevention Conference held June 9 - 12, 2007, in Washington, D.C. The analysis demonstrates that the "Natural History Staggered Start" trial design currently being used in the Flurizan Phase 3 study can provide the same level of disease modification support as the cross-over trial designs, which are challenged by ethical concerns, dropout bias and complications.

A disease modifying therapy for Alzheimer's disease (AD) is one that has an impact on the underlying pathology of the disease and thus slows the rate of a patient's decline over the course of long-term treatment. In contrast, the currently available AD medicines are believed to treat the symptoms of AD without impacting the underlying disease process or providing long lasting benefit. The development of robust methods to demonstrate disease modification in AD clinical trials has been a controversial issue in the field, and to date, there have been no studies that provide convincing evidence of disease modification in AD. Two clinical trial designs that could provide evidence for disease modification were originally proposed for AD studies over 10 years ago by Paul Leber, then the head of the Division of Neuropharmacological Drug Products of the FDA. These designs have come to be known as the "Randomized Withdrawal" and "Staggered Start" designs and are based on measuring clinical outcomes in a cross-over type study.

In the randomized withdrawal design, patients are withdrawn from therapy after a defined period to determine whethe
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Myriad Genetics Presents Tumor Origin Technology at AACR
2. Myriad Genetics Presents Azixas Mode of Action at AACR
3. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
4. Genetics Journal Thimerosal/Autism Study the Best Science Drug Company Money Can Buy
5. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
6. ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial in B-Cell Chronic Lymphocytic Leukemia
7. Seattle Genetics Highlights Data on its Proprietary Antibody-Drug Conjugate Technology at AACR
8. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
9. Expression Genetics, Inc. Announces Successful Completion of Phase I Trial of Gene-Based IL-12 for Treatment of Ovarian Cancer
10. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
11. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
Post Your Comments:
(Date:5/15/2008)...ts obtained with a newly cleared device to identif...erest that are associated with c...ss., May 15 /- InfraReDx, Inc. today,...Royal Oak, Mich., have,successfully used its LipiS...going a cardiac catheterization. This is the first...
(Date:5/15/2008)...tzerland, May 15 /- Ergonex Pharma to... Administration (FDA) has,granted orphan drug desi...y,arterial hypertension (PAH). Terguride is curren...trial in Europe., "The FDA,s grant of orphan drug...trengthens our development program by offering reg...
(Date:5/15/2008)..., Fla., May 15 /- Tigris Pharmaceutic...rative Research and,Development Agreement (CRADA) ...orate on clinical and preclinical development of A...opment. AFP-464 is converted to,metabolites which ...n and,apoptosis., This is part of a four-year CRA...
(Date:5/15/2008)...tunity Remains for an Antiplatelet Therapy that, C...he Combination of Plavix/Iscover and Aspirin, ... WALTHAM, Mass., May 15 /- Decision ... advisory firms for pharmaceutical and,healthcare ...ent offers,improvement in patient compared to Sano...
Breaking Medicine Technology:First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System 2First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System 3First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System 4Terguride Receives FDA Orphan Drug Designation for the Treatment of Pulmonary Arterial Hypertension 2Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute 2Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute 3Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 3Purging the plantain pests in Africa 2284 1Purging the plantain pests in Africa 2284 2New understanding of how big molecules bind will lead to better drugs synthetic organic materials 12402 1New understanding of how big molecules bind will lead to better drugs synthetic organic materials 12402 2New understanding of how big molecules bind will lead to better drugs synthetic organic materials 12402 3Fast Food Ads Fueling Obesity Among Hispanic Kids 12399 1Fast Food Ads Fueling Obesity Among Hispanic Kids 12399 2First Lady Laura Bush Visits AED Netmark Malaria Control Project in Ghana 12394 1First Lady Laura Bush Visits AED Netmark Malaria Control Project in Ghana 12394 2
... -- Treatment of,coronary artery disease (CAD) app...g, according to a study published today in The,Ame...n rates for heart attacks (acute myocardial,infarc...ssibly due,to broader use of preventive treatments...ines in risk factors like smoking. , The study is ...
...d Play Key Role in the,Treatment of Influenza and ...ire-FirstCall/ --,ImmuneRegen BioSciences, a wholl.... , announced today that data obtained by,the Comp...that the,compound has potential value as a co-ther...ed in animal models of influenza and acute,radiati...
Other Medicine Technology:Hospitalization Rates for Coronary Artery Disease Decline in the,U.S. 2Hospitalization Rates for Coronary Artery Disease Decline in the,U.S. 3ImmuneRegen BioSciences Announces Promising Data on Homspera,Suggesting Potential as a Co-Therapeutic Agent 2ImmuneRegen BioSciences Announces Promising Data on Homspera,Suggesting Potential as a Co-Therapeutic Agent 3ImmuneRegen BioSciences Announces Promising Data on Homspera,Suggesting Potential as a Co-Therapeutic Agent 4
(Date:5/16/2008)... Campaign to Visit Portland to Rally Residents to ... Milk Their Diets, PORTLAND, Ore., May 16 /PRNew...s and downs of different fad diets -- which seem t...hemlines. Yet, long-term success has been,slim. Tw...f Portland,residents -- remain overweight or obese...
(Date:5/16/2008)...First and Only Therapy Approved to Treat Both Type... Cholesterol Welchol Recently Add...6 /PRNewswire/ -- Daiichi Sankyo, Inc. (DSI),annou...her demonstrate that,Welchol(TM) (colesevelam HCl)...based therapy, significantly lowers blood glucose ...
(Date:5/16/2008)... Revolution Health CEO: ,We need to get the sy...wswire-FirstCall/ -- Internet visionary,turned e-h...ging trends in,public policy, technology and consu..."shake the snow globe," simultaneously creating di...ion in American health care., The America Online ...
(Date:5/16/2008)... ROCHESTER, Minn. -- Adding a second monoclonal a...reatment of diffuse large B-cell lymphoma, accordi...th Central Cancer Treatment Group (NCCTG) ( http:/...is were released May 15 as part of the 44th Annual...ogy. , Researchers found that 95 percent of pat...
Breaking Medicine News(10 mins):Health News:Message to Oregon Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 2Health News:Message to Oregon Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 3Health News:Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes 2Health News:Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes 3Health News:Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes 4Health News:Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes 5Health News:Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes 6Health News:Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes 7Health News:'Case' in Point: Patient Control of Data Critical Catalyst for Online Health Care Revolution 2Health News:'Case' in Point: Patient Control of Data Critical Catalyst for Online Health Care Revolution 3Health News:'Case' in Point: Patient Control of Data Critical Catalyst for Online Health Care Revolution 4Health News:Adding epratuzumab to standard therapy 2
... for reduction on VAT for condoms, to be reduced f...bolishment of VAT on condoms, the best that can be...ked a re-categorization of condoms from a luxury i...hornberry, Labor MP for Islington South, has propo...
...rusalem researchers report that another health ben...lesterol in blood. As a result it reduces the inci...at heart patients who eat one grapefruit daily can...olesterol in their blood in comparison to patients...
...vement in the field of pharmacology; the number of...onsiderably over the recent years. It is however t...ad to disastrous consequences, including death. //...e ingredients that can interact or work against ea...
...ve disinfection of anthrax spores was highlighted ...tly. // It has now been found that anthrax spores ...ed disinfection methods due to their improved abil...r of water pipes. The researchers have therefore ...
Other Medicine News:Health News:One fruit that has captured the health benefit sector is Grapefruit! 2Health News:Drug Combinations Could Be Dangerous 2Health News:Anthrax Spores May Resist Water Treatment 2
A Merger of True Equals,Symbia T6, a True Point SPECTCT system, combines a dual-detector variable angle gamma camera with a six-slice CT scanner for advanced oncology, neurology, and cardiology app
...stent technology with no compromises. It's the ste... results. With S670's discrete, low-profile delive...excellent clinical results you want. S670, the fir...es. It's the stent that delivers like a balloon-wi...
The balloon catheter is a coaxial, dual balloon design and is made of PEBAX Material. Gas is contained in the inner balloon enhancing procedural safety. Radiopaque markings enhance the visibility of
For support, strength and control in your interventions, the RunWay Guide Catheter's large lumen and high-performance design represents a new era in guide catheters.
Medicine Products: